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Treatment of the hormone refractory prostate cancer cell line DU 145 with sublethal concentrations of chemotherapeutic
drugs has been reported to sensitise these cells to Fas mediated apoptosis. However, the mechanism by which this occurs has
not been determined. Our group has shown that inhibition of JNK activity completely abrogates the effects of
chemotherapeutic drugs. Using anisomycin, a potent JNK agonist, we have demonstrated a role for JNK in Fas mediated
apoptosis in DU 145 cells. Inhibition of Caspase 8 and Caspase 9 completely inhibits this process which suggests that DU 145
cells require mitochondrial ampliﬁcation of the Fas apoptotic signal. Furthermore, we have shown that inhibition of Fas
mediated apoptosis is an early event in DU 145 cells, occurring upstream of Caspase 8 cleavage. It is hoped that identifying
the target of JNK will allow novel therapies to be developed for the treatment of hormone refractory prostate cancer. Such
therapies are especially important because no single or combined treatment to date has signiﬁcantly prolonged survival in
patients with hormone refractory prostate cancer.
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Prostate cancer is the second most prevalent malignancy in the
EU after lung cancer with about 200000 new cases diagnosed
and over 35000 deaths each year. In England and Wales,
15000 new cases and 8000 deaths are registered each year
(Parkin et al, 2001). Although the prognosis is good for indivi-
duals with localised tumours, 10–20% of patients are diagnosed
with metastatic prostate cancer (Crawford et al, 1999). These
patients are usually treated with hormone ablation therapy which
results in immediate tumour regression and temporary relief for
the patient. However, hormone refractory prostate cancer invari-
ably develops within 2–3 years of hormone ablation (Petrylak,
1999). This slowly proliferating cancer is extremely difﬁcult to
treat and the prognosis for the patient is generally poor. Over
the past 5 years, chemotherapy has been used to improve the
quality of life in patients with metastatic, hormone-refractory
prostate cancer. No treatment has yet been found that cures
the disease or even signiﬁcantly prolongs survival (Petrylak,
1999).
Apoptosis, or programmed cell death (PCD), is characterised
by morphological features including chromatin condensation,
nuclear fragmentation, cell shrinkage, membrane blebbing and
apoptotic body formation (Kerr et al, 1972). Although a variety
of different environmental insults and signalling pathways can
stimulate apoptosis in cells, most of these signals converge at a
family of cysteine proteases called the caspases. Like many
proteases, they are synthesised in an inactive form and cleavage
into active caspases is essential for the proliferation of the apop-
totic signal. Caspases can be divided into two main subfamilies,
initiator caspases and effector caspases (Wolf and Green, 1999).
The Fas receptor is a member of the Tumour Necrosis Factor
receptor superfamily and is expressed at the plasma membrane
in a variety of tissues. Ligation of Fas ligand or a cross-linking
antibody to the Fas receptor induces apoptosis in susceptible cells.
Fas receptor clustering results in the recruitment and auto-clea-
vage of the initiator caspase, Procaspase 8, at the plasma
membrane. Active Caspase 8 proceeds to cleave downstream cellu-
lar targets including the effector Caspases 3 and 7, and the Bcl-2
family member Bid (Peter and Krammer, 1998). Often an ampli-
ﬁcation step is required for Caspase 3 cleavage and morphological
apoptosis. Caspase 8 cleaves Bid into tBid, a pro-apoptotic Bcl-2
family member that induces cytochrome c release and apoptosome
formation. This ampliﬁcation loop through the mitochondrion
drives the apoptotic programme in type II cells (Scafﬁdi et al,
1999b).
DU 145 cells, a hormone refractory prostate adenocarcinoma,
are highly resistant to Fas mediated apoptosis in vitro. In a study
performed using cell lines derived from prostate tumours with
different pathological stages including DU 145, it was observed that
ALVA-31 and PPC-1 were sensitive to Fas mediated apoptosis.
These were reported to be isolated from primary prostatic
tumours. In contrast, the cell lines LNCaP, DU 145 and PC-3 were
resistant. These cell lines were reported to be derived from distant
metastases. The authors correlated prostate cancer disease progres-
sion with resistance to Fas. Furthermore they suggest that this
phenomenon may explain, at least in part, the inability to treat
hormone refractory prostate cancer (Hedlund et al, 1998). The
two other cell lines used in this study, JCA-1 and TSU-Pr1 have
since been reclassiﬁed as bladder cancer cell lines (van Bokhoven
et al, 2001).
In order to study the resistance of hormone refractory prostate
cancer to chemotherapy, the effects of chemotherapeutic drugs on
DU 145 cells was explored (Uslu et al, 1997; Costa-Pereira and
Cotter, 1999). Our group discovered that sublethal concentrations
of camptothecin, a novel topoisomerase I inhibitor, sensitised DU
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www.bjcancer.com145 cells to Fas mediated apoptosis by 20-fold (Costa-Pereira and
Cotter, 1999). Activation of the stress kinase JNK was found to be
essential in potentiating Fas mediated apoptosis (Costa-Pereira et
al, 2000). In this study, we use anisomycin, a potent activator of
JNK, to underscore the role played by JNK in Fas mediated apop-
tosis in DU 145 cells.
MATERIALS AND METHODS
Cell lines and reagents
DU 145 and Jurkat T cells were obtained from American Type
Culture Collection (ATCC, Rockville, MD, USA). Cell culture
reagents were purchased from Gibco BRL (UK) with the excep-
tion of foetal calf serum (FCS) (Sigma, UK). Anisomycin was
purchased from Sigma (UK) and was dissolved in DMSO at
a concentration of 5 mg ml
71. A working stock at 10 mgm l
71
in RPMI was prepared from the original stock. A FACScan
(Beckton Dickinson, BD Biosciences, Germany) and Cell Quest
software Version 3.3 (Beckton Dickinson) were used for all ﬂow
cytometry assays. Annexin V-FITC was purchased from Bender
MedSystems (Germany) and propidium iodide (PI) from Sigma
(UK). TUNEL reagents were obtained from Roche (UK) and
JC-1 was purchased from Molecular Probes (Netherlands). The
antibodies used in this study were mouse anti-Fas IgM clone
CH11, mouse anti-Fas IgG for ﬂow cytometry (Bender MedSys-
tems, Germany), phospho-JNK (Thr183/Tyr185) clone G9 and
rabbit anti-Caspase 3 (Cell Signalling Technology, New England
Biolabs UK), rabbit anti-JNK1 and rabbit anti-Fas ligand (Santa
Cruz, USA), rabbit anti-Bid (BioSource International, USA),
rabbit anti-human caspase 8 (R&D Systems, UK) and mouse
anti-b Actin clone AC-15 (Sigma, UK). All FITC and R-
Phycoerythrin conjugated secondary antibodies were purchased
from Sigma (UK) and HRP conjugated secondary antibodies
from DAKO (Denmark). The Caspase inhibitors z-IETD-fmk
and z-LEHD-fmk were obtained from Calbiochem (CN Bios-
ciences UK). Enhanced Chemiluminescence Reagent (ECL) was
purchased from Amersham Biosciences (UK).
Cell culture and treatment
DU 145 cells were cultured in RPMI 1640 medium supplemented
with 5% FCS, 2 mM L-Glutamine in the presence of 10 IU ml
71
penicillin-streptomycin. Jurkat cells were cultured in RPMI 1640
medium containing 10% FCS, 2 mM L-Glutamine and 10 IU ml
71
penicillin-streptomycin. Cells were cultured at 378C in a humidi-
ﬁed atmosphere with 5% CO2 and were routinely subcultured
every 2–3 days. Prior to every experiment DU 145 cells were
grown to 75% conﬂuency and Jurkats were resuspended at 0.5
million ml
71. DU 145 cells were pretreated with 250 ng ml
71
anisomycin for 10 min before addition of 200 ng ml
71 anti-Fas
IgM.
Annexin V binding and propidium iodide uptake assay
DU 145 and Jurkat cells were incubated with 250 ng ml
71 aniso-
mycin and 200 ng ml
71 anti-Fas IgM for 8 h. The cells were
subsequently harvested, washed once in PBS and resuspended in
Annexin V binding buffer (150 mM NaCl, 18 mM CaCl2,1 0m M
HEPES, 5 mM KCl, 1 mM MgCl2). FITC conjugated Annexin V
(1 mgm l
71), which binds speciﬁcally to apoptotic cells, was added
to each sample and incubated at ambient temperature for 5 min.
Propidium iodide (50 mgm l
71), excluded from viable cells, was
added immediately prior to reading the samples on the FACScan.
Where indicated the Caspase 8 and Caspase 9 inhibitors were incu-
bated for 10 min at 50 mM prior to treating the cells with
anisomycin or Fas.
DNA fragmentation assay
TUNEL measures DNA fragmentation using the enzyme Terminal
deoxynucleotide Transferase (TdT) to transfer multiple biotin
labelled nucleotides to the 3' hydroxyl groups of DNA. FITC
conjugated Avidin can be used to stain this modiﬁed label. Using
ﬂow cytometry, cells with fragmented DNA in their nuclei display
an increased ﬂuorescent signal in the FL-1 channel relative to
untreated cells.
DU 145 and Jurkat cells were harvested, washed twice in PBS
and ﬁxed slowly in 1% paraformaldehyde (PFA) on ice for
15 min. The cells were washed twice in PBS and resuspended in
25 ml reaction mixture (TdT buffer, 2.5 mM CoCl2, Bio-16-dUTP
and TdT enzyme). The DNA labelling reaction was allowed to
proceed for 30 min at 378C. The cells were washed twice in PBS
and resuspended in 50 ml staining buffer (56SSC, 5% w v
71 dry
milk, 16Avidin-FITC and 1/10006Triton X-100). The cells were
stained for 30 min at room temperature in the dark and washed
twice in PBS. Flow cytometry and Cell Quest were used to collect
and analyse the data.
Fas receptor expression
0.5610
6 cells were harvested per sample and washed twice in PBS.
They were stained for 1 h at 48C with 20 mgm l
71 of the primary
antibody mouse anti-Fas IgG. After another two washes with PBS,
the cells were stained with the FITC conjugated secondary antibody
sheep anti-mouse IgG for 1 h at 48C in the dark. Cells stained with
secondary antibody alone were used to compensate for intrinsic
ﬂuorescence and non-speciﬁc binding of the secondary antibody.
The cells were washed twice in PBS and the presence of Fas R
was detected in FL-1 using a FACScan ﬂow cytometer.
Fas ligand expression
0.5610
6 cells were harvested per sample and were ﬁxed slowly in
ice cold 1% PFA for 15 min. The cells were permeabilised over-
night in 70% ethanol (7208C) and stained with 2 mgm l
71
rabbit anti-Fas ligand or 2 mgm l
71 rabbit irrelevant IgG in IFATX
(4% FCS, 150 mM NaCl, 10 mM HEPES, 0.1% sodium azide, 0.1%
Triton X-100) for 1 h at 48C. Subsequently, the cells were stained
for 1 h with 12 mgm l
71 FITC-conjugated anti-rabbit IgG in the
dark at 48C. Fas ligand expression was analysed on the FACScan
using Cell Quest software.
Mitochondrial membrane depolarisation
The lipophilic cation called JC-1 is cell permeable and selectively
accumulates in the mitochondria of live cells. When depolarisation
of the mitochondria occurs, the emission spectrum of JC-1 changes
from 590 nm (its aggregated form) to 530 nm (its monomeric
form) and this can be analysed using ﬂow cytometry. Depolarisa-
tion of mitochondria results in an increase in ﬂuorescence in the
FL-1 channel, and a concurrent decrease in the FL-2 channel in
ﬂow cytometers.
DU 145 cells were harvested, resuspended in RPMI+10% FCS
and 2.5 mgm l
71 JC-1 was added. The samples were incubated at
room temperature for 20 min in the dark, washed twice in PBS
and read on the FACScan. Analysis was carried out using Cell
Quest software.
SDS–PAGE and Western blot
Protein extracts were prepared from cells using RIPA lysis buffer
(50 mM Tris, pH 7.4; 150 mM NaCl; 1 mM each of NaF, NaVO4
and EGTA; 1% NP40; 0.25% sodium deoxycholate; 0.2 mM
phenylmethylsulphonyl ﬂuoride; 1 mgm l
71 each of antipain, apro-
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71 leupeptin; 4.0 mgm l
71 pepsta-
tin) and 30 mg of protein was loaded in each lane of an SDS
polyacrylamide gel. Electrophoresis and Western blotting was
subsequently carried out. Non-speciﬁc protein binding sites on
the membrane were blocked using 5% dry milk in TBS+0.1%
Tween-20 for 1 h at room temperature. The membrane was stained
with primary and peroxidase conjugated secondary antibodies
according to the manufacturer’s recommended protocol and
labelled protein was detected using ECL.
RESULTS
Anisomycin activates JNK and sensitises DU 145 cells to
Fas mediated apoptosis
The hormone refractory cell line DU 145 is highly resistant to Fas
mediated apoptosis. This appears to be a common event during
prostate cancer progression. Cell lines isolated from early stages
of prostate cancer are usually sensitive to the Fas activating anti-
body anti-Fas IgM. Those cell lines derived from secondary
tumours after hormone ablation therapy are generally resistant to
Fas (Hedlund et al, 1998). Our group has previously shown that
camptothecin, a Topoisomerase I inhibitor, sensitises DU 145 cells
to Fas mediated apoptosis (Costa-Pereira and Cotter, 1999). Addi-
tional analysis identiﬁed activation of the stress kinase JNK as an
integral event in this process (Costa-Pereira et al, 2000). In order
to understand the mechanisms behind this sensitisation process
we have used anisomycin, an agonist of the JNK pathway in
mammalian cells, which is often used in studies involving JNK
because of its speciﬁcity and potency in activating the JNK path-
way. As expected, we found that anisomycin can act in synergy
with Fas to induce apoptosis in DU 145 cells. Phosphatidylserine
ﬂipping, an early event during apoptosis was detected with
FITC-conjugated Annexin-V using ﬂow cytometry. Propidium
iodide was used as a counter stain to distinguish between early
and late apoptosis (Figure 1A). Flow cytometry was also used to
detect DNA fragmentation, another hallmark of apoptosis, in
TUNEL labelled DU 145 cells following incubation with anisomy-
cin (250 ng ml
71) and anti-Fas IgM (200 ng ml
71) (Figure 1B).
This rapid onset of DNA fragmentation in our system is indicative
of a stronger apoptotic stimulus when anisomycin is used to sensi-
tise DU 145 cells to anti-Fas IgM in comparison with other
cytotoxic drugs. Extensive DNA fragmentation was only observed
after 48 h when CPDD and CHX were used (Rokhlin et al, 1997;
Uslu et al, 1997). Numerous reports have been described in the
literature of both Caspase 8 dependent and Caspase 8 independent
JNK activation during Fas mediated apoptosis. We used an anti-
body speciﬁc to phosphorylated JNK to assess the status of JNK
activation in DU 145 cells after 1 and 8 h incubation with aniso-
mycin (250 ng ml
71) and anti-Fas IgM (200 ng ml
71). We
veriﬁed that JNK is not activated either transiently (1 h) or
prolonged (8 h) with anti-Fas IgM (Figure 1c). As expected, aniso-
mycin was found to stimulate prolonged JNK activation in DU 145
cells. An in vitro kinase assay using radiolabelled
32P was used to
verify the activity of JNK (data not shown).
Fas receptor and Fas ligand are not up-regulated by
anisomycin in DU 145 cells
Various reports have shown that down-regulation of Fas receptor
or Fas ligand expression occurs in some cancer cells. In addition,
expression of Fas ligand has been reported to increase following
JNK activation in Jurkat cells (Herr et al, 2000). This increase in
Fas ligand expression caused an increase in the kinetics of Fas
mediated apoptosis. We assessed the expression of both Fas recep-
tor and Fas ligand over an 8 h period (1,2,4 and 8 h) following
incubation with anisomycin (250 ng ml
71) or anti-Fas IgM
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Figure 1 Anisomycin sensitised the androgen independent cell line DU
145 to Fas mediated apoptosis. DU 145 cells were pre-treated with aniso-
mycin (250 ng ml
71) for 10 min before the addition of anti-Fas IgM
(200 ng ml
71). Cells were stained with Annexin V and PI (A) or TUNEL
(B) after 8 h incubation as described in the Materials and Methods section.
Flow cytometry was used to visualise the extent of apoptosis. Data are re-
presentative of at least three independent experiments. (C) Anisomycin,
not anti-Fas IgM, stimulates prolonged JNK activation in DU 145 cells. Wes-
tern blot analysis was used to detect active JNK in untreated DU 145 cells,
or cells treated with anisomycin (250 ng ml
71), anti-Fas IgM
(200 ng ml
71) or both anisomycin and anti-Fas IgM for 1 and 8 h. Total
JNK expression was determined to ensure equal protein loading.
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71). Cell surface Fas receptor was expressed on 95% of
DU 145 cells and its expression was not found to change following
treatment with anisomycin or anti-Fas IgM (Figure 2A). Similarly,
Fas ligand was expressed in 90% of DU 145 cells and expression
was not increased in DU 145 cells following incubation with aniso-
mycin or anti-Fas IgM (Figure 2B). Western blot analysis
conﬁrmed that the expression of Fas receptor and Fas ligand was
not upregulated following drug treatment (data not shown).
Activation of Caspase 3 during Fas mediated apoptosis
In order to delineate the mechanisms by which DU 145 cells are
sensitised to Fas mediated apoptosis we analysed the major events
during Fas mediated apoptosis. Most apoptotic stimuli converge on
Caspase 3, a cysteine protease and the main effecter caspase during
Fas mediated apoptosis. Once activated, Caspase 3 cleaves a variety
of substrates responsible for the morphological and biochemical
changes observed during apoptosis (Nicholson, 1999). We found
that both anisomycin and anti-Fas IgM treatment alone were insuf-
ﬁcient for Caspase 3 activation in DU 145 cells. However, co-
incubation of cells with both anisomycin and anti-Fas IgM clearly
potentiates the activation of Caspase 3 in DU 145 cells (Figure 3A).
Anti-Fas IgM treated Jurkats are used as a positive control for
Caspase 3 activation. Flow cytometric analysis conﬁrmed that
70% of DU 145 cells expressed the active form of Caspase 3 follow-
ing treatment with both anisomycin and anti-Fas IgM (data not
shown).
Mitochondrial membrane depolarisation
It has been shown that Fas receptor activation is often not sufﬁ-
cient for direct activation of Caspase 3. These cells, known as
type II cells, require an ampliﬁcation signal through the mitochon-
drion. Caspase 8 cleaves and activates Bid, a pro-apoptotic Bcl-2
family member. This results in mitochondrial membrane depolar-
isation, cytochrome c release and ampliﬁcation of the Fas
apoptotic signal through Caspase 9 (Kim et al, 2000). Here we used
the voltage sensitive, lipophilic ﬂuorescent probe JC-1 to analyse
the extent of mitochondrial membrane depolarisation in DU 145
cells. Depolarisation of the mitochondrion causes an increase in
FL-1 ﬂuorescence and a concomitant decrease in FL-2 ﬂuorescence
when analysed by ﬂow cytometry (Cossarizza et al, 1993). We
found that stimulation of DU 145 cells for 8 h with anisomycin
(250 ng ml
71) or anti-Fas IgM (200 ng ml
71) alone did not result
in permeability transition of the mitochondria (Figure 3B). This
suggested that Fas mediated apoptosis is inhibited up-stream of
mitochondrial depolarisation in DU 145 cells. Incubation of DU
145 cells with both anisomycin (250 ng ml
71) and anti-Fas IgM
(200 ng ml
71) resulted in mitochondrial depolarisation. We found
that incubation of DU 145 cells with 50 mM z-LEHD-fmk (a
Caspase 9 speciﬁc inhibitor) completely abrogated apoptosis when
incubated with anisomycin (250 ng ml
71) and anti-Fas IgM
(200 ng ml
71) (Figure 3C). This suggested that mitochondrial
membrane depolarisation and cytochrome c release are essential
events for Fas mediated apoptosis in DU 145 cells.
Caspase 8 activation in DU 145 cells
The proximal caspase in the Fas apoptotic pathway is Caspase 8.
Recruitment and auto-cleavage of Procaspase 8 occurs following
Fas receptor activation in sensitive cells. Active Caspase 8 is tetra-
meric, consisting of two P14 and two P10 subunits. Using Western
blot analysis, we found that Caspase 8 is not cleaved in DU 145
cells following treatment with anti-Fas IgM (200 ng ml
71) (Figure
4A). Therefore, we concluded that inhibition of Fas mediated
apoptosis occurred upstream of Caspase 8 activation in DU 145
cells. Caspase 8 cleavage products were only evident following
incubation with both anisomycin (250 ng ml
71) and anti-Fas
IgM (200 ng ml
71). This was also true for the Caspase 8 substrate
Bid (Figure 4B). Z-IETD-fmk (50 mM), an irreversible inhibitor
speciﬁc to Caspase 8, was found to completely protect against
apoptosis induced by anisomycin (250 ng ml
71) and anti-Fas
IgM (200 ng ml
71) (Figure 4C). Interestingly, this inhibitor also
abolishes apoptosis associated with anisomycin alone. This suggests
that low levels of Caspase 8 activation occur in DU 145 cells
following incubation with anisomycin alone. A dose titration of
z-IETD-fmk conﬁrmed that this inhibitor speciﬁcally inhibits
Caspase 8 at 50 mM (data not shown). FLIP is a family of proteins
structurally related to Caspase 8 that inhibit Fas mediated apopto-
sis when overexpressed in cells (Scafﬁdi et al, 1999a). Two main
isoforms of FLIP are expressed in cells, a long splice variant
(FLIPL) and a short splice variant (FLIPS). Using Western blot
analysis we found that DU 145 cells express FLIPS. However,
expression of this caspase 8 inhibitor does not appear to decrease
following incubation with anisomycin (data not shown).
DISCUSSION
The sensitivity of prostate cancer cell lines to Fas mediated apop-
tosis has been shown to correlate with tumour stage, grade and
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Figure 2 Flow cytometric analysis of Fas receptor (A) or Fas ligand (B)
expression in untreated DU 145 cells or following 8 h incubation with ani-
somycin (250 ng ml
71), anti-Fas IgM (200 ng ml
71) or both. Data are re-
presentative of at least three independent experiments and similar data
were obtained for incubations of 1, 2 and 4 h.
JNK sensitises DU 145 cells to Fas mediated apoptosis
JF Curtin and TG Cotter
1191
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(10), 1188–1194E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s
Untreated
Anisomycin
Anti-Fas IgM
Anisomycin and
anti-Fas IgM
C
o
u
n
t
s
8%
10%
9%
32%
FL1
B
1                 2               3                 4               5
ProCaspase 3
Active
Caspase 3
Actin
A
Anti-Fas IgM Anisomycin Untreated Anisomycin
and anti-Fas
IgM
70%
60%
50%
40%
30%
20%
10%
0%
A
p
o
p
t
o
s
i
s
C
Figure 3 (A) Untreated DU 145 (1) cells or cells treated for 8 h with
anisomycin (250 ng ml
71)( 2), anti-Fas IgM (200 ng ml
71)( 3) or both
(4) were stained for Caspase 3 cleavage. Jurkats treated with anti-Fas
IgM (200 ng ml
71) for 4 h were used as a positive control (5). (B) Mito-
chondrial membrane depolarisation (DC) was detected in DU 145 cells
using the lipophilic JC-1 probe, as described previously. DC was only ob-
served in DU 145 cells treated for 8 h with both anisomycin
(250 ng ml
71) and anti-Fas IgM (200 ng ml
71). (C) DU 145 cells were
pre-treated with 50 mM z-LEHD-fmk (white columns) or a DMSO control
(black columns) for 10 min before treating with anisomycin (250 ng ml
71)
and anti-Fas IgM (200 ng ml
71) for 8 h. Apoptosis was assessed by staining
the cells with Annexin V-FITC and PI. The error bars represent standard
deviation after three independent experiments.
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Figure 4 Inhibition of Fas mediated apoptosis occurs upstream of Cas-
pase 8 cleavage in DU 145 cells. (A) Western blot analysis of Caspase 8
in untreated DU 145 cells (1) or following incubation with anisomycin
(250 ng ml
71)( 2), anti-Fas IgM (200 ng ml
71)( 3) or both (4) for 8 h. Un-
treated (5) and anti-Fas IgM treated (200 ng ml
71 anti-Fas IgM, 4 h) (6)
Jurkat cells were used as a positive control for the P14 and P10 Caspase
8 cleavage products. b-Actin was also probed to ensure equal protein load-
ing. (B) Bid expression and cleavage was analysed by Western blot in un-
treated DU 145 cells (1) or in cells incubated with anisomycin
(250 ng ml
71)( 2), anti-Fas IgM (200 ng ml
71)( 3) or both (4) for 8 h. Jur-
kats untreated (5) or treated with anti-Fas IgM (200 ng ml
71) for 4 h (6)
are used as a positive control. (C) DU 145 cells were pre-treated with
50 mM z-IETD-fmk (white columns) or a DMSO control (black columns)
for 10 min before treating with anisomycin and anti-Fas IgM as before.
Apoptosis was determined by staining with both Annexin V and PI after
8 h. Data is representative of three independent experiments.
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group and others have shown that DU 145 cells are highly resistant
to Fas mediated apoptosis. Co-treatment with sublethal concentra-
tions of chemotherapeutic drugs including cyclohexamide (CHX),
cisplatin (CPDD), etoposide (VP16) and camptothecin was found
to sensitise these cells to Fas mediated apoptosis (Uslu et al,
1997; Rokhlin et al, 1998; Costa-Pereira and Cotter, 1999) indepen-
dently of new protein synthesis (Frost et al, 1999). Our group
subsequently identiﬁed a key role for JNK in this process. DU
145 cells were co-treated with camptothecin and anti-Fas IgM
and were completely protected from apoptosis by anti-sense oligo-
nucleotides speciﬁc for JNK (Costa-Pereira et al, 2000). In
addition, camptothecin is a potent activator of JNK and sensitises
DU 145 cells to Fas mediated apoptosis to a much greater extent
than CHX, CPDD and VP16 (Costa-Pereira and Cotter, 1999).
We have shown that anisomycin, a potent activator of JNK in
mammalian cells, sensitises DU 145 cells to Fas mediated apoptosis
to a similar extent as camptothecin. We felt that because camp-
tothecin is also a topoisomerase I inhibitor and the mechanisms
by which it activates JNK are unclear, anisomycin would present
a better option for delineating the effects of JNK during Fas
induced apoptosis.
Binding of Fas ligand, or Fas activating antibodies, to Fas receptor
results in DISC formation and prolonged JNK activation by either
Caspase 8 dependent or Caspase 8 independent mechanisms (Chang
et al, 1998; Rudel et al, 1998; Charette et al, 2001; Graves et al,
2001). We have shown that stimulating Fas R with anti-Fas IgM
alone does not result in JNK activation in DU 145 cells. We found
that mitochondrial membrane depolarisation only occurs in DU 145
cells co-stimulated with anisomycin and anti-Fas IgM. In addition
Caspase 8 and Bid were only cleaved following incubation with both
anisomycin and anti-Fas IgM. This suggests that anisomycin sensi-
tises DU 145 cells to Fas mediated apoptosis at a point upstream
of Caspase 8 cleavage, probably during DISC formation.
There are some reports of caspase independent cell death follow-
ing Fas R activation. These are mediated through kinases such as RIP
and ASK1 (Holler et al, 2000; Charette et al, 2001). However, we
have shown that both Caspase 8 and Caspase 9 inhibitors completely
abrogate apoptosis induced by anisomycin and anti-Fas IgM in DU
145 cells. Therefore, anisomycin sensitised DU 145 cells to apoptosis
mediated by Fas that is dependent on both Caspase 8 activity to
initiate the pathway and Caspase 9 activity as an ampliﬁcation step
required for Caspase 3 activation and apoptosis.
The principal apoptotic pathway activated by many anti-cancer
drugs is the Fas apoptotic pathway. DU 145 cells incubated with
toxic concentrations of 9-amino camptothecin were found to
increase Fas receptor and Fas ligand expression and decrease c-
FLIPS. Apoptosis could be inhibited by transient overexpression
of c-FLIPS, suggesting that 9-amino camptothecin induces apopto-
sis through the Fas apoptotic pathway (Chatterjee et al, 2001).
However, we found no evidence for increased Fas receptor or
Fas ligand expression following incubation with anisomycin. We
did observe a decrease in Fas ligand expression after apoptotic
body formation in cells incubated with both anisomycin and
anti-Fas IgM. This is most probably due to the shedding of
membrane bound Fas ligand and is irrelevant to the initiation of
apoptosis in these cells. We also analysed FLIPS expression but
no changes were observed following treatment with anisomycin.
Chemotherapeutic drugs have also been reported to activate the
Fas apoptotic pathway without upregulation of Fas ligand or Fas
receptor. Apoptosis induced by CPDD, VP16 and vinblastine
(VB) was shown involve Fas receptor clustering and Caspase 8 acti-
vation and was independent of Fas ligand in various colon cancer
cells and leukaemia cells (Micheau et al, 1999). It is possible that
anisomycin is inducing Fas receptor aggregation independently of
anti-Fas IgM but this is highly unlikely in light of our results. It
seems more probable that JNK activation enhances Fas receptor
aggregation and DISC formation through its interaction with some
key regulator of DISC formation in DU 145 cells.
Conventional chemotherapy has been unsuccessful in treating
prostate cancer. No single or combined chemotherapy regime has
been identiﬁed that signiﬁcantly enhances long term survival. This
may be due, at least in part, to the resistance developed to Fas
mediated apoptosis in hormone refractory prostate cancer. We
have sensitised DU 145 cells to Fas mediated apoptosis using the
JNK agonist anisomycin. In addition we have traced the effects
of JNK to a point upstream of Caspase 8 cleavage. It is hoped that
by understanding this process novel drug targets may be identiﬁed
that improve the treatment of hormone refractory prostate cancer.
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